Polyoxidonium pills 12mg N10
Condition: New product
988 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Azoxymere Bromide
Release form
Pills
Pharmacological effect
Immunomodulatory drug. The drug increases the body's resistance against bacterial, fungal and viral infections. The basis of the mechanism of the immunomodulating action of the drug Polyoxidonium is to increase the ability of leukocytes to phagocytose microorganisms, stimulate the production of cytokines that activate the immune system at initially lowered levels, and enhance the formation of antibodies to infectious agents. focus of infection. In addition, Polyoxidonium activates lymphoid cells found in regional lymph nodes, namely B cells that produce secretory IgA. For sublingual use, Polyoxidonium activates lymphoid cells found in the nasal cavity, Eustachian tubes, oropharynx, bronchi. In addition, Polyoxidonium activates the bactericidal properties of saliva. For oral administration, Polyoxidonium also activates lymphoid cells located in the lymph nodes of the intestine. The result is an increase in the resistance of the respiratory tract, gastrointestinal tract and ENT organs to infectious agents. In addition to the immunomodulatory effect, Polyoxidonium has a pronounced detoxin. and antioxidant activity, has the ability to excrete toxins from the body, salts of heavy metals, inhibits lipid peroxidation Dov. These properties are determined by the structure and high molecular nature of the drug Polyoxidonium. The use of the drug Polyoxidonium against the background of secondary immunodeficiency states improves efficiency and shortens the duration of treatment, significantly reduces the use of antibiotics, bronchodilators, GCS, lengthen the period of remission. The drug is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have allergenic, mutagenic, embryotoxic, teratogenic and can erogennogo action.
Pharmacokinetics
Absorption: Polyoxidonium after oral administration is rapidly absorbed from the gastrointestinal tract, bioavailability is approximately 50%.Cmax in plasma is reached 3 hours after ingestion. Pharmacokinetics of the drug is linear (plasma concentration is proportional to the dose taken). Distribution: Polyoxidonium is a hydrophilic compound. The apparent Vd is about 0.5 l / kg, which suggests that the drug is distributed mainly in the intercellular fluid. The period of semi-absorption is 35 min. Does not cumulate. Metabolism and excretion: In the body it is hydrolyzed to oligomers, which are derived mainly by the kidneys. T1 / 2 - 18 h.
Indications
Treatment and prevention of infectious and inflammatory diseases (viral, bacterial and fungal etiology) that are not amenable to standard therapy, both in the acute stage and in the remission stage, in adults and adolescents older than 12 years. -inflammatory diseases of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear; - allergic diseases complicated by recurrent bacterial, fungal and viral infections (including pollinosis, br Onchial asthma middle ear; - in immunocompromised individuals for the prevention of influenza and other acute respiratory infections in the pre-epidemic period; - for the correction of secondary immunodeficiencies resulting from aging or exposure to adverse factors.
Contraindications
Children age up to 12 years; - increased individual sensitivity to the drug. The drug should be used with caution in acute renal failure, as well as in lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
Precautionary measures
Caution should be used in acute renal failure.
Use during pregnancy and lactation
Use during pregnancy and lactation is contraindicated (clinical experience is not available). Excretion of azoxymere bromide with breast milk has not been studied.
Side effects
No adverse effects of Polyoxidonium were reported.
Overdose
Currently, cases of overdose Polyoxidonium not reported.
Interaction with other drugs
Drug interaction is not established. Polyoxidonium is compatible with antibiotics, antiviral, antifungal and antihistamine drugs, bronchodilators, GCS, cytostatics, beta adrenomimetics.
special instructions
Do not exceed the specified dose and duration of the course of treatment. Influence on the ability to drive vehicles and control mechanisms. The drug does not affect the ability to drive a car and control mechanisms.